Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Synergy CHC ( (SNYR) ) has provided an announcement.
On May 29, 2025, Synergy CHC Corp. resolved $12,713,858 of its debt to Knight Therapeutics International S.A. through a combination of cash repayment, early payment discount, and conversion into equity. Subsequently, on June 11, 2025, the company issued a pre-funded common stock purchase warrant to Knight, allowing the purchase of up to 428,570 shares of common stock. This strategic financial maneuver is expected to impact the company’s operations by reducing debt and potentially altering its equity structure, which may influence its market positioning and stakeholder interests.
The most recent analyst rating on (SNYR) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Synergy CHC stock, see the SNYR Stock Forecast page.
Spark’s Take on SNYR Stock
According to Spark, TipRanks’ AI Analyst, SNYR is a Neutral.
Synergy CHC presents a mixed outlook. While the stock is undervalued based on its P/E ratio, significant financial risks due to high leverage and liquidity issues are concerning. The company’s bearish technical indicators and lack of a clear positive earnings call narrative further weigh down the score. On the positive side, corporate events such as leadership changes and strategic partnerships suggest potential future growth.
To see Spark’s full report on SNYR stock, click here.
More about Synergy CHC
Average Trading Volume: 1,095,525
Technical Sentiment Signal: Hold
Current Market Cap: $19.65M
For a thorough assessment of SNYR stock, go to TipRanks’ Stock Analysis page.